Jennifer Jones
Psychiatric/Mental Health · Alexandria, LANPI 1558752303
Payments from drug & device makers
Across 921 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Axsome Therapeutics, Inc.$1K
- Alkermes, Inc.$1K
- plus $5K from 23 others
What the payments were for
- Food & beverage$14,47598%
- Education$2302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 168 | $2,374 |
| AbbVie | 120 | $1,948 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 83 | $1,393 |
| Otsuka America Pharmaceutical, Inc. | 83 | $1,271 |
| Axsome Therapeutics, Inc. | 64 | $1,196 |
| Alkermes, Inc. | 69 | $1,062 |
| Teva Pharmaceuticals USA, Inc. | 48 | $969 |
| Johnson & Johnson | 43 | $922 |
| Lundbeck LLC | 56 | $845 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $623 |
| Corium, LLC | 32 | $417 |
| Acadia Pharmaceuticals Inc | 30 | $264 |
| Sunovion Pharmaceuticals Inc. | 17 | $251 |
| E.r. Squibb & Sons, L.L.C. | 12 | $227 |
| Braeburn Inc. | 8 | $180 |
| Vanda Pharmaceuticals Inc. | 12 | $155 |
| Supernus Pharmaceuticals, Inc. | 7 | $123 |
| Indivior Inc. | 7 | $122 |
| Noven Therapeutics, LLC | 3 | $72 |
| Ironshore Pharmaceuticals Inc. | 4 | $62 |
| Hikma Pharmaceuticals USA | 2 | $37 |
| Eisai Inc. | 3 | $35 |
| Collegium Pharmaceutical, Inc. | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $30 |
| Sage Therapeutics, LLC | 1 | $26 |
| Bausch Health US, LLC | 1 | $20 |
| Tris Pharma Inc | 1 | $18 |
| OWP Pharmaceuticals, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$125
How this compares
$14,705 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 56 | $476,852 |
| RexultiBrexpiprazole | 245 | $383,249 |
| Austedo XrDeutetrabenazine | 53 | $360,172 |
| Invega SustennaPaliperidone Palmitate | 87 | $263,690 |
| VraylarCariprazine Hcl | 93 | $147,106 |
| Invega TrinzaPaliperidone Palmitate | 11 | $93,754 |
| AustedoDeutetrabenazine | 14 | $72,691 |
| NuplazidPimavanserin Tartrate | 13 | $54,512 |
| CaplytaLumateperone Tosylate | 33 | $54,203 |
| TrintellixVortioxetine Hydrobromide | 45 | $20,626 |
| Risperdal ConstaRisperidone Microspheres | 25 | $15,918 |
| FetzimaLevomilnacipran Hcl | 23 | $11,115 |
| AbilifyAripiprazole | 12 | $11,031 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $10,691 |
| Lurasidone Hcl | 103 | $8,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,374 | $476,85256 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $969 | $432,86367 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,271 | $383,249245 claims |
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $922 | $373,362123 claims |
| AbbVieVraylar, Fetzima | $1,948 | $158,221116 claims |
| Acadia Pharmaceuticals IncNuplazid | $264 | $54,51213 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,393 | $54,20333 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $623 | $31,31770 claims |
| E.r. Squibb & Sons, L.L.C.Abilify | $227 | $11,03112 claims |
| Eisai Inc.Dayvigo | $35 | $7,95224 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone | $37 | $2,11611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Alexandria
- Monica GriffithAlexandria$13K
- Amy PaulAlexandria$11K
- Kimberly ColstonAlexandria$10K
- Kimberly RiversAlexandria$9K
- Alyssa CzudekAlexandria$8K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.